Avidity Biosciences Valuation
| RNA Stock | USD 72.90 0.08 0.11% |
At this time, the firm appears to be overvalued. Avidity Biosciences shows a prevailing Real Value of $67.62 per share. The current price of the firm is $72.9. Our model approximates the value of Avidity Biosciences from analyzing the firm fundamentals such as Return On Equity of -0.32, shares outstanding of 154.48 M, and Operating Margin of (15.13) % as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Avidity Biosciences' valuation include:
Price Book 5.9547 | Enterprise Value | Enterprise Value Ebitda (5.72) | Price Sales 539.0623 | Enterprise Value Revenue 450.7518 |
Overvalued
Today
Please note that Avidity Biosciences' price fluctuation is very steady at this time. Calculation of the real value of Avidity Biosciences is based on 3 months time horizon. Increasing Avidity Biosciences' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Avidity Biosciences is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Avidity Stock. However, Avidity Biosciences' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 72.9 | Real 67.62 | Target 74.64 | Hype 72.9 | Naive 72.99 |
The real value of Avidity Stock, also known as its intrinsic value, is the underlying worth of Avidity Biosciences Company, which is reflected in its stock price. It is based on Avidity Biosciences' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Avidity Biosciences' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Avidity Biosciences helps investors to forecast how Avidity stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Avidity Biosciences more accurately as focusing exclusively on Avidity Biosciences' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Avidity Biosciences' intrinsic value based on its ongoing forecasts of Avidity Biosciences' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Avidity Biosciences' closest peers. If more than one evaluation category is relevant for Avidity Biosciences we suggest using both methods to arrive at a better estimate.
Avidity Biosciences Cash |
|
Avidity Biosciences Total Value Analysis
Avidity Biosciences is at this time estimated to have company total value of 9.41 B with market capitalization of 11.25 B, debt of 6.8 M, and cash on hands of 398.22 M. Please note that company total value may be misleading and is a subject to accounting gimmicks. We encourage investors to carefully check all of the Avidity Biosciences fundamentals before making security assessment based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
9.41 B | 11.25 B | 6.8 M | 398.22 M |
Avidity Biosciences Investor Information
About 98.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 4.19. Avidity Biosciences had not issued any dividends in recent years. Based on the key indicators related to Avidity Biosciences' liquidity, profitability, solvency, and operating efficiency, Avidity Biosciences is not in a good financial situation at this time. It has a very high odds of going through financial crisis in March.Avidity Biosciences Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Avidity Biosciences has an asset utilization ratio of 0.7 percent. This suggests that the Company is making $0.006968 for each dollar of assets. An increasing asset utilization means that Avidity Biosciences is more efficient with each dollar of assets it utilizes for everyday operations.Avidity Biosciences Profitability Analysis
Based on Avidity Biosciences' profitability indicators, Avidity Biosciences may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in March. Profitability indicators assess Avidity Biosciences' ability to earn profits and add value for shareholders.Net Loss | First Reported 2014-03-31 | Previous Quarter -157.3 M | Current Value -174.4 M | Quarterly Volatility 45.2 M |
For Avidity Biosciences profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Avidity Biosciences to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Avidity Biosciences utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Avidity Biosciences's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Avidity Biosciences over time as well as its relative position and ranking within its peers.
Avidity Biosciences Earnings per Share Projection vs Actual
The next projected EPS of Avidity Biosciences is estimated to be -1.230025 with future projections ranging from a low of -1.6325 to a high of -0.81. Avidity Biosciences' most recent 12-month trailing earnings per share (EPS TTM) is at -4.19. Please be aware that the consensus of earnings estimates for Avidity Biosciences is based on EPS before non-recurring items and includes expenses related to employee stock options.Avidity Biosciences Earnings Estimation Breakdown
The calculation of Avidity Biosciences' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Avidity Biosciences is estimated to be -1.230025 with the future projection ranging from a low of -1.6325 to a high of -0.81. Please be aware that this consensus of annual earnings estimates for Avidity Biosciences is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-1.63 Lowest | Expected EPS | -0.81 Highest |
Avidity Biosciences Earnings Projection Consensus
Suppose the current estimates of Avidity Biosciences' value are higher than the current market price of the Avidity Biosciences stock. In this case, investors may conclude that Avidity Biosciences is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Avidity Biosciences' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2026 | Current EPS (TTM) | |
| 14 | 77.37% | 0.0 | -1.230025 | -4.19 |
Avidity Biosciences Ownership Allocation
Avidity Biosciences holds a total of 154.48 Million outstanding shares. The majority of Avidity Biosciences outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Avidity Biosciences to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Avidity Biosciences. Please pay attention to any change in the institutional holdings of Avidity Biosciences as this could imply that something significant has changed or is about to change at the company. Also note that nearly two million four hundred twenty-five thousand three hundred eighteen invesors are currently shorting Avidity Biosciences expressing very little confidence in its future performance.Avidity Biosciences Profitability Analysis
The company reported the last year's revenue of 10.9 M. Reported Net Loss for the year was (322.3 M) with loss before taxes, overhead, and interest of (467.32 M).Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Avidity Biosciences' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Avidity Biosciences and how it compares across the competition.
About Avidity Biosciences Valuation
The stock valuation mechanism determines Avidity Biosciences' current worth on a weekly basis. Our valuation model uses a comparative analysis of Avidity Biosciences. We calculate exposure to Avidity Biosciences's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Avidity Biosciences's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 12.5 M | 13.2 M | |
| Pretax Profit Margin | (34.01) | (35.71) | |
| Operating Profit Margin | (39.99) | (41.99) | |
| Net Loss | (34.01) | (35.71) | |
| Gross Profit Margin | 0.70 | 0.74 |
Avidity Biosciences Current Valuation Indicators
Valuation refers to the process of determining the present value of Avidity Biosciences and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Avidity we look at many different elements of the entity such as Avidity's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Avidity Biosciences, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Avidity Biosciences' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Avidity Biosciences' worth.Complementary Tools for Avidity Stock analysis
When running Avidity Biosciences' price analysis, check to measure Avidity Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Avidity Biosciences is operating at the current time. Most of Avidity Biosciences' value examination focuses on studying past and present price action to predict the probability of Avidity Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Avidity Biosciences' price. Additionally, you may evaluate how the addition of Avidity Biosciences to your portfolios can decrease your overall portfolio volatility.
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios |